RYBELSUS^® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus:

• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;
  
• in combination with other medicinal products for the treatment of diabetes (see clinical trials in the Product Monograph for patient populations and drug combinations tested).
  

RYBELSUS^® is not indicated for use in type 1 diabetes or for the treatment of diabetic ketoacidosis. RYBELSUS^® is not indicated for use in pediatric patients. Greater sensitivity of some older individuals cannot be ruled out. Therapeutic experience in patients ≥75 years of age is limited.

Consult the RYBELSUS^® Product Monograph at RYBELSUSPM-E.ca or here for important information on:

• Contraindications in patients with personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); hypersensitivity to the formulation or container; pregnancy or breastfeeding
• Most serious warnings and precautions about risk of thyroid C-cell tumours
• Other relevant warnings and precautions about CV effects; hypoglycemia with concomitant use of insulin secretagogues or insulin; dizziness (initial dose escalation); driving and operating machinery; pancreatitis; hypersensitivity; diabetic retinopathy; renal insufficiency and dehydration; fertility; hepatic impairment; acute events of gall bladder disease; GLP-1 RA class potential for severe GI disease (ileus) 
• Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling us at 1-800-465-4334.